Heparin-induced thrombocytopenia

Platelets

Volumn , Issue , 2007, Pages 861-886

  Chong, Beng H ^a  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 62549106738     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-012369367-9/50810-7     Document Type: Chapter

References (207)

1. Chong B.H. Heparin induced thrombocytopenia. Br J Haematol 1995, 89:431-439.
2. Chong B.H. Heparin induced thrombocytopenia. Blood Reviews 1988, 2:108-114.
3. Warketin T.E., Chong B.H., Greinacher A. Heparin induced thrombocytopenia: Towards consensus. Thromb Haemost 1998, 79:1-7.
4. Ortel T.L., Chong B.H. New treatment options for heparin-induced thrombocytopenia. Sem Hematol 1998, 35(4:5):3-8.
5. Copley A.L., Robb T.P. Studies on platelets III: The effect of heparin in vivo on the platelet count in mice and dogs. Am J Clin Pathol 1942, 12:563-570.
6. Quick A.J., Shanberge J.N., Stefanini M. The effect of heparin on platelets in vivo. J Lab Clin Med 1948, 33:1424-1430.
7. Fidlar E., Jaques L.B. The effect of commercial heparin on the platelet count. J Lab Clin Med 1948, 33:1410-1413.
8. Gollub S., Ulin A.W. Heparin-induced thrombocytopenia in man. J Lab Clin Med 1962, 59:430-435.
9. Davey M.G., Lander H. Effect of injected heparin on platelet levels in man. J Lab Clin Pathol 1968, 21:55-99.
10. Natelson E.A., Lynch E.C., Alfrey, et al. Heparin-induced thrombocytopenia: An unexpected response to treatment of consumption coagulopathy. Ann Intern Med 1969, 71:1121-1125.
11. Weismann R.E., Tobin R.W. Arterial embolism occurring during systemic heparin therapy. AMA Archives of Surgery 1958, 76:219-227.
12. Roberts B., Rosato E.F. Heparin-A cause of arterial emboli?. Surgery 1964, 55:803-808.
13. Rhodes G.R., Dixon R.H., Silver D. Heparininduced thrombocytopenia with thrombotic and hemorrhagic manifestations. Surg Gynecol Obstet 1973, 136:409-416.
14. Fratantoni J.C., Pollet R., Gralnick H.R. Heparin-induced thrombocytopenia: Confirmation of diagnosis with in vitro methods. Blood 1975, 45:395-401.
15. Nelson J.C., Lerner R.G., Goldstein R., et al. Heparin-induced thromboctyopenia. Arch Intern Med 1978, 138:548-552.
16. Cimo P.L., Moake J.L., Weinger R.S., et al. Heparin-induced thrombocytopenia: Association with a platelet aggregating factor and arterial thromboses. Am J Hematol 1979, 6:125-133.
17. Towne J.B., Bernhard V.M., Hussey C., et al. White clot syndrome, peripheral vascular complications of heparin therapy. Arch Surg 1979, 114:372-377.
18. Klein H.G., Bell W.R. Disseminated intravascular coagulation during heparin therapy. Intern Med 1974, 80:477-478.
19. Bell W.R., Tomasulo P.A., Alving B.M., et al. Thrombocytopenia occurring during the administration of heparin: A prospective study in 52 patients. Ann Intern Med 1976, 85:155-160.
20. Chong B.H., Pitney W.R., Castaldi P.A. Heparin-induced thrombocytopenia: Association of thrombotic complication with a heparin-dependent IgG antibody which induced platelet aggregation, release and thromboxane synthesis. Lancet 1982, ii:1246-1248.
21. Chong B.H., Berndt M.C. Heparin-induced thrombocytopenia. Blut 1989, 58:53-57.
22. Salzman E.W., Rosenberg R.D., Smith M.H., et al. Effect of heparin and heparin fractions on platelet aggregation. J Clin Invest 1980, 65:64-73.
23. Chong B.H., Ismail F. The mechanism of heparininduced platelet aggregation. Eur J Haematol 1989, 43:245-251.
24. Holmer E., Lindahl U., Bäckström G., et al. Anticoagulant activities and effects on platelets of a heparin fragment with high affinity for antithrombin. Thromb Res 1980, 18:861-869.
25. Mikhaildis D.P., Barradas M.A., Jeremy J.Y., et al. Heparin-induced platelet aggregation in anorexia nervosa and in severe peripheral vascular disease. Eur J Clin Invest 1985, 15:313-319.
26. Burgess J.K., Chong B.H. The platelet proaggregating and potentiating effects of unfractionated heparin, low molecular weight heparin and heparinoid in intensive care patients and healthy controls. Eur J Haematol 1997, 58:270-285.
27. Blahut B., Kramar H., Vinazzer H., et al. Substitution of antithrombin III in shock and DIC: A randomized study. Thromb Res 1985, 39:81-89.
28. Balduini C.L., Noris P., Bertolino G., et al. Thromb Haemost 1993, 69:522-523.
29. Amiral J., Bridey F., Dreyfus M., et al. Platelet factor 4 complexed to heparin is the target for antibodies generated in heparin induced thrombocytopenia [letter]. Thromb Haemost 1992, 68:95-96.
30. Horne M.K., Hutchinson K.J. Simultaneous binding of heparin and platelet factor-4 to platelets: Further insights into the mechanism of heparin-induced thrombocytopenia. Am J Hematol 1998, 58:24-30.
31. Visentin G.P., Moghaddam M., Collins J.L., et al. Antibodies associated with heparin-induced thrombocytopenia (HIT) report confor mational changes in platelet factor 4 (PF4) induced by linear polyanionic compounds [abstr.]. Blood 1997, 90(suppl 1):460a.
32. Horne M.K., Chao E.S. The effect of molecular weight on heparin binding to platelets. Br J Haematol 1990, 74:306-312.
33. Greinacher A., Alban S., Dummel V., et al. Characterization of the structural requirements for a carbohydrate based anticoagulant with a reduced risk of inducing the immunological type of heparin-associated thrombocytopenia. Thromb Haemost 1995, 74:886-892.
34. Horne M.K. Heparin-induced thrombocytopenia 2000, 113-126. Basel, Marcel Dekker, New York. T.E. Warkentin, A. Greinacher (Eds.).
35. Dawes J., Pumphrey C.W., McLaren K.M., et al. The in vivo release of human platelet factor 4 by heparin. Thromb Res 1982, 27:65-76.
36. Warkentin T.E., Levine M.N., Hirsh J., et al. Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. N Engl J Med 1995, 332:1330-1335.
37. Visentin G.P., Malik M., Cyganiak K.A., et al. Patients treated with unfractionated heparin during open heart surgery are at high risk to form antibodies reactive with heparin: Platelet factor 4 complexes. J Lab Clin Med 1996, 128:376-383.
38. Burgess J.K., Lopez J.A., Berndt M.C., et al. Quinine-dependent antibodies bind a restricted set of epitopes on the glyooprotein 1b-1x complex: Charactarization of the epitopes. Blood 1998, 92:2366-2373.
39. Chee, M., Vun, & Chong, B. H. (unpublished data).
40. Li Z.Q., Park K.S., Sachais B.S., et al. Defining a second epitope for heparin-induced thrombocytopenia/ thrombosis antibodies using KKO, a murine HIT - like monoclonal antibody. Blood 2002, 99:1230-1236.
41. Zeporen L., Li Z.Q., Park K.S., et al. Defining an antigenic epitope on platelet factor 4 associated with heparininduced thrombocytopenia. Blood 1998, 92:3250-3259.
42. Rauova L., Poncz M., McKenzie S.E., et al. Ultra large complexes of PF4 and heparin are central to the pathogenesis of heparin-induced thrombocytopenia. Blood 2005, 105:131-138.
43. Newman P., Chong B.H. Heparin-induced thrombocytopenia: The major antigenic epitope is on the modified platelet factor 4 and not on heparin. Br J Haematol 1999, 107:303-309.
44. Kelton J.G., Sheridan D., Santos A., et al. Heparininduced thrombocytopenia: Laboratory studies. Blood 1998, 72:925-930.
45. Chong B.H., Ismail F., Chesterman C.N., et al. Heparin-induced thrombocytopenia: Mechanism of interaction of the heparin-dependent antibody with platelets. Br J Haematol 1989, 73:235-240.
46. Newman P., Chong B.H. Heparin-induced thrombocytopenia: New evidence for the dynamic binding of purtied anti-pf4-heparin antibodies to platelets and the resulting activation. Blood 2000, 96:182-187.
47. Warkentin T.E., Hayward C.P.M., Boshkov L.K., et al. Sera from patients with heparin-induced thrombocytopenia generated platelet-derived microparticles with procoagulant acitivity: An explanation for the thrombotic complications of heparin-induced thrombocytopenia. Blood 1994, 84:3691-3699.
48. Chong B.H., Grace C.S., Rosenberg M.C. Heparin-induced thrombocytopenia: Effects of heparin platelet antibody on platelets. Br J Haematol 1981, 49:531-540.
49. Warkentin T.E. Heparin-induced thrombocytopenia: IgG-mediated platelet activation, platelet microparticle generation, and altered procoagulant/anticoagulant balance in the pathogenesis of thrombosis and venous limb gangrene complicating heparin-induced thrombocytopenia. Transfus Med Rev 1996, 10:249-258.
50. Amiral J., Wolf M., Fischer A.M., et al. Pathogenicity of IgA and/or IgM antibodies to heparin-PF4 complexes in patients with heparin-induced thrombocytopenia. Br J Haematol 1996, 92:954-959.
51. Warkentin T.E. Heparin-induced thrombocytopenia: Pathogenesis and management. Br J Hematol 2003, 121:1365-2141.
52. Amiral J., Peynaud-Debayle E., Wolf M., et al. Generation of antibodies to heparin-PF4 complexes without thrombocytopenia in patients treated with unfractionated or low molecular weight heparin. Am J Hematol 1996, 52:90-95.
53. Brandt J.T., Isenhart C.E., Osborne J.M., et al. On the role of platelet FcγRIIa phenotype in heparin-induced thrombocytopenia. Thromb Haemost 1995, 74:1564-1572.
54. Burgess J.K., Lindeman R., Chesterman C.N., et al. Single amino acid mutation of Fcγ receptor is associated with the development of heparin-induced thrombocytopenia. Br J Haematol 1995, 91:761-766.
55. Denomme G.A., Warkentin T.E., Horsewood P., et al. Activation of platelets by sera containing IgG1 heparin-dependent antibodies: An explanation for the predominance of the FcγRIIa "low responder" (His131) gene in patients with hepain-induced thrombocytopenia. J Lab Clin Med 1997, 130:278-284.
56. Arepally G., McKenzie S.E., Jiang X-M., et al. FcγRIIA H/R131 polymorphism, subclass-specific IgG antiheparin/ platelet factor 4 anti bodies and clinical course in patients with heparin-induced thrombocytopenia and thrombosis. Blood 1997, 89:370-375.
57. Bachelot-Loza C., Saffroy R., Lasne D., et al. Importance of the FcγRIIa-Arg/His-131 polymorphism in heparin-induced thrombocytopenia diagnosis. Thromb Haemost 1998, 79:523-528.
58. Carlsson L.E., Santoso S., Baurichter G., et al. Heparin-induced thrombocytopenia: New insights into the impact of the FcγRIIa-R-H131 polymorphism. Blood 1998, 92:1526-1531.
59. Amiral J., Marfaing-Koka A., Wolf M., et al. Presence of auto-antibodies to interleukin-8 or neutrophilactivating peptide-2 in patients with heparin-associated thrombocytopenia. Blood 1996, 88:410-416.
60. Reilly M.P., Taylor S.M., Hartman N.K., et al. Heparin-induced thrombocytopenia/thrombosis in a transgenic mouse model demonstrates the requirement for human platelet factor 4 and platelet activation through Fcγ R II A. Blood 2001, 98:2442-2447.
61. Cines D.B., Tomaski A., Tannenbaum S. Immune endothelial-cell injury in heparin-associated thrombocytopenia. N Engl J Med 1987, 316:581-589.
62. Visentin G.P., Ford S.E., Scott J.P., et al. Antibodies from patients with heparin-induced thrombocytopenia/ thrombosis are specific for platelet factor 4 complexed with heparin or bound to endothelial cells. J Clin Invest 1994, 93:81-88.
63. Arepally G.M., Mayer I.M. Antibodies from patients with heparin-induced thrombocytopenia stimulate monocytic cells to express tissue factor and secrete interleukin-8. Blood 2001, 98:1252-1254.
64. Gallus A.S., Goodall K.T., Beswick W., et al. Heparin-associated thrombocytopenia: A case report and prospective study. Aust N Z J Med 1980, 10:25-31.
65. Kakkasseril J.S., Cranley J.J., Panke T., et al. Heparin-induced thrombocytopenia: A prospective study of 142 patients. J Vasc Surg 1985, 2:382-384.
66. Holm H.A., Eika C., Laake K. Thrombocytes and treatment with heparin from porcine mucosa. Scand J Haematol 1980, 36(suppl 1):81-84.
67. Eika C., Godal H.C., Laake K., et al. Low incidence of thrombocytopenia during treatment with hog mucosa and beef lung heparin. Scand J Haematol 1980, 25:19-24.
68. Powers P.J., Kelton J.G., Carter C.J. Studies of the frequency of heparin-associated thrombocytopenia. Thromb Res 1984, 33:439-443.
69. Cipolle R.J., Rodvold K.A., Seifert R., et al. Heparin-associated thrombocytopenia: A prospective evaluation of 211 patients. Ther Drug Monit 1983, 5:205-211.
70. Lee D.H., Warkentin T.E. Heparin-induced thrombocytopenia 2004, 107-148. Basel, Marcel Dekker, New York. 3rd ed. T.E. Warkentin, A. Greinacher (Eds.).
71. Bell W.R., Royall R.M. Heparin-associated thrombocytopenia: A comparison of three heparin preparations. N Engl J M 1980, 303:902-907.
72. Ansell J., Stepchuk N., Kumar R., et al. Heparininduced thrombocytopenia: A prospective study. Thromb Haemost 1980, 43:61-65.
73. Bailey R.T., Ursick J.A., Heirn K.L., et al. Heparin-associated thrombocytopenia: A prospective comparison of bovine lung heparin intestinal heparin. Drug Intell Clin Pharm 1986, 20:374-378.
74. Green D., Martin G.J., Shoichet S.H., et al. Thrombocytopenia in a prospective, randomized, doubleblind trial of bovine and porcine heparin. Am J Med Sci 1984, 288:60-64.
75. Schmitt B.P., Adelman B. Heparin-associated thrombocytopenia: A critical review and a pooled analysis. Am J Med Sci 1993, 305:208-215.
76. Powers P.J., Cuthbert D., Hirsh J. Thrombocytopenia found uncommonly during heparin therapy. JAMA 1979, 241:2396-2397.
77. Malcolm I.D., Wigmore T.A., Steinbrecher U.P. Heparin-associated thrombocytopenia: Low frequency in 104 patients treated with heparin of intestinal mucosal origin. Can Med Assoc J 1979, 120:1086-1088.
78. Girolami B., Prandoni P., Stefani P.M., et al. The incidence of heparin-induced thrombocytopenia in hospitalised medical patients treated with subcutaneous unfractionated heparin: A prospective cohort study. Blood 2003, 101:2955-2959.
79. Amiral J., Peynaud-Debayle E., Wolf M., et al. Generation of antibodies to heparin-PF4 complexes without thrombocytopenia in patients treated with unfractionated or low-molecular weight heparin. Am J Hematol 1998, 52:90-95.
80. Ansell J.E., Price J.M., Shah S., et al. Heparininduced thrombocytopenia: What is its real frequency?. Chest 1985, 88:878-882.
81. Saffle J.R., Russon J., Dukes G.E., et al. The effect of low-dose heparin therapy on serum platelet and transaminase levels. J Surg Res 1980, 28:297-305.
82. Olin J., Graor R. Heparin-associated thrombocytopenia. N Eng J Med 1981, 304:609.
83. Romeril K.R., Anzimlt C.M.H., Hamer J.W., et al. Heparin-induced thrombocytopenia: Case reports and a prospective study. N Z Med J 1982, 95:267-269.
84. Weitberg A.B., Spremulli E., Cummings F.J. Effect of low-dose heparin on the platelet count. South Med J 1982, 75:190-192.
85. Monreal M., Lafoz E., Salvador R., et al. Adverse effects of three different forms of heparin therapy: Thrombocytopenia, increased transaminases, and hyperkalemia. Eur J Clin Pharmacol 1989, 37:415-418.
86. Rao A.K., White G.C., Sherman L., et al. Low incidence of thrombocytopenia with porcine muccossal heparin. A prospective multicentre study. Arch Intern Med 1989, 149:1285-1288.
87. Johnson R.A., Lazarus K.H., Henry D.H. Heparin-induced thrombocytopenia: A prospective study. Am J Hematol 1984, 17:349-353.
88. Ayars G.H., Tikoff G. Incidence of thrombocytopenia in medical patients on "mini-dose" heparin prophylaxis. Am Heart J 1980, 99:816. (letter).
89. Leyvraz P.F., Bachmann F., Hoek J., et al. Prevention of deep vein thrombosis after hip replacement: Randomised comparison between unfractionated heparin and low molecular weight heparin. Br Med J 1991, 303:543-548.
90. Ganzer D., Gutezeit A., Mayer G., et al. Thromboemolieprophylaxe als Auslöser Thrombembolischer Komplicationen. Eine Untersuchung zur Inzidenz de Heparininduzierten Thrombozytopenie (HIT) Type II. Z Orthop 1997, 135:543-549.
91. Louridas G. Heparin-induced thrombocytopenia. S Afr J Surg 1991, 29:50-52.
92. Trossaert M., Gaillard A., Commin P.L., et al. High incidence of anti-heparin/platelet factor 4 antibodies after cardiopulmonary bypass. Br J Haematol 1998, 101:653-655.
93. Pouplard C., May M.A., Iochmann S., et al. Antibodies to platelet factor 4-heparin after cardiopulmonary bypass in patients anticoagulated with unfractionated heparin or a low-molecular-weight heparin: Clinical implications for heparin-induced thrombocytopenia. Circulation 1999, 99:2530-3536.
94. Warkentin T.E., Sheppard J.A., Horsewood P., et al. Impact of the patient population on the risk for heparin-induced thrombocytopenia. Blood 2000, 96:1703-1708.
95. Visentin G.P., Mali M., Cyganiak K.A., et al. Patients treated with unfractionated heparin during open heart surgery are at high risk to form antibodies reactive with heparin platelet factor 4 complexes. J Lab Clin Med 1996, 128:376-383.
96. Bauer T.L., Arepally G., Konkle B.A., et al. Prevalence of heparin-associated antibodies without thrombosis in patients undergoing cardiopulmonary bypass surgery. Circulation 1997, 95:1242-1246.
97. Savi P., Chong B.H., Greinacher A., et al. Effect of fondaparinux on platelet activation in the presence of heparin-dependent antibodies: A blinded comparative multicentre study with unfractinated heparin. Blood 2005, 105:139-144.
98. Turpie A.G.G., Gallus A.S., Hoek J.A. For the pentasaccharide investigators: A synthetic pentasaccharide for the prevention of deep-vein thrombosis after total hip replacement. N Engl J Med 2001, 344:619-625.
99. The Rembrandt Investigators Treatment of proximal deep-vein thrombosis with a novel synthetic compound (SR90107A/ORG31540) with pure anti-factor Xa activity: A phase 2 evaluation. Circulation 2000, 102:2726-2731.
100. Fausett M.B., Vogtlander M., Lee R.M., et al. Heparin-induced thrombocytopenia is rare in pregnancy. Am J Obstet Gynecol 2001, 185:148-152.
101. Lepercq J., Conard J., Borel-Derlon A., et al. Venous thromboembolism during pregnancy: A retrospective study of enoxaparin safety in 624 pregnancies. Br J Obstet Gynaecol 2001, 108:1134-1140.
102. Warkentin T.E., Sigouin C.S. Gender and risk of immune heparin-induced thrombocytopenia. Blood 2002, 100:17a. (abstract).
103. Heeger P.S., Backstrom J.T. Heparin flushes and thrombocytopenia [letter]. Ann Intern Med 1986, 105:143.
104. Rama B.N., Haake R.E., Bander S.J., et al. Heparin-flush associated thrombocytopenia-induced hemorrhage: A case report. Nebr Med J 1991, 76:392-394.
105. Laster J., Silver D. Heparin-coated catheters and heparin-induced thrombocytopenia. J Vasc Surg 1988, 7:667-672.
106. Warkentin T.E. Heparin-induced thrombocytopenia 2004, 105-106. Basel, Marcel Dekker, New York. 3rd ed. T.E. Warkentin, A. Greinacher (Eds.).
107. Rice L., Attisha W.K., Drexler A., et al. Delayedonset heparin-induced thormbocytopenia. Ann Int Med 2002, 136:210-215.
108. Warkentin T.E., Kelton J.G. Delayed-onset heparin-induced thrombocytopenia and thrombosis. Ann Int Med 2001, 135:502-506.
109. Warkentin T.E., Kelton J.G. Timing of heparininduced thrombocytopenia (HIT) in relation to previous heparin use: Absence of an anamnestic immune response, and implications for repeat heparin use in patients with a history of HIT [abstr.]. Blood 1998, 92(suppl 1):182a.
110. Warkentin T.E., Sheppard J.I., Horsewood P., et al. Impact of the patient population on the risk for heparininduced thrombocytopenia. Blood 2000, 96:1703-1708.
111. Boshkov L.K., Warkentin T.E., Hayward C.P.M., et al. Heparin-induced thrombocytopenia and thrombosis: Clinical and laboratory studies. Br J Haematol 1993, 84:322-328.
112. Warkentin T.E., Elavathil L.J., Hayward C.P.M., et al. The pathogenesis of venous limb gangrene associated with heparin-induced thrombocytopenia. Ann Intern Med 1997, 127:804-812.
113. Srinivasan A.F., Rice L., Bartholomew J.R., et al. Warfarin-induced skin necrosis and venous limb gangrene in the setting of heparin-induced thrombocytopenia. Arch Intern Med 2004, 164:66-70.
114. Warkentin T.E., Hong A.P. Upper limb deep venous thrombosis and central venous catheter complicating immune heparin-induced thrombocytopenia (HIT). Blood 1998, 101:3049-3051.
115. Van der Weyden M.B., Hunt H., McGrath K., et al. Delayed-onset heparin-induced thrombocytopenia: A potentially malignant syndrome. Med J Aust 1983, 2:132-135.
116. Kyritsis A.P., Williams E.C., Schutta H.S. Cerebral venous thrombosis due to heparin-induced thrombocytopenia. Stroke 1990, 21:1503-1505.
117. Arthur C.K., Grant S.J.B., Murray W.K., et al. Heparin-associated acute adrenal insufficiency. Aust NZ J Med 1985, 15:454-455.
118. Bleasel J.F., Rasko J.E.J., Rickard K.A., et al. Acute adrenal insufficiency secondary to heparin-induced thrombocytopenia-thrombosis syndrome. Med J Aust 1992, 157:192-193.
119. Meyer-Lindenberg A., Quenzel E-M., Bierhoff E., et al. Fatal cerebral venous sinus thrombosis in heparininduced thrombocytopenia. Eur Neurol 1997, 37:191-192.
120. Celoria G.M., Steingart R.H. and Banson B. et al., Coumarin skin necrosis in a patient with heparin-induced thrombocytopenia - a Case Report. Angiology.
121. Cohen G.R., Hall J.C., Yeast J.D., et al. Heparininduced cutaneous necrosis in a postpartum patient. Obste Gynecol 1988, 72:498-499.
122. Popov D., Zarrabi M.H., Foda H., et al. Pseudopulmonary embolism: Acute respiratory distress in the syndrome of heparin-induced thrombocytopenia. Am J Kidney Dis 1997, 29:449-452.
123. Warkentin T.E., Soutar R.L., Panju A., et al. Acute systemic reactions to intravenous bolus heparin therapy: Characterization and relationship to heparin-induced thrombocytopenia [abstr]. Blood 1992, 80(suppl 1):160a.
124. Warkentin T.E., Hirte H.W., Anderson D.R., et al. Transient global amnesia associated with acute heparin-induced thrombocytopenia. Am J Med 1994, 97:489-491.
125. Chong B.H. Diagnosis, treatment and pathophysiology of immune-mediated thrombocytopenia. Critical Rev Oncol Hematol 1995, 20:271-296.
126. Chong B.H., Eisbacher M. Pathophysiology and laboratory testing of heparin-induced thrombocytopenia. Sem in Haematol 1998, 35:3-8.
127. Sheridan D., Carter C., Kelton J.G. A diagnostic test for heparin-induced thrombocytopenia. Blood 1986, 67:27-30.
128. Schnell M.K., Giordano K.J., Henry M., et al. Diagnosis of heparin-induced thrombocytopenia (HIT): Comparison of methods. Transfusion 1998, 38:98S. (suppl.).
129. Greinacher A., Michels J., Kiefel V., et al. A rapid and sensitive test for diagnosing heparin-associated thrombocytopenia. Thromb Haemost 1991, 66:734-736.
130. Chong B.H., Burgess J., Ismail F. The clinical usefulness of the platelet aggregation test for the diagnosis of heparin-induced thrombocytopenia. Thromb Haemost 1993, 69:344-350.
131. Stewart M.W., Etches W.S., Boshkov L.K., et al. Heparin-induced thrombocytopenia: An improved method of detection based on lumi-aggregometry. Br J Haematol 1995, 91:173-177.
132. Lee D.P., Warkentin T.E., Denomme G.A., et al. A diagnostic test for heparin-induced thrombocytopenia: Detection of platelet microparticles using flow cytometry. Br J Haematol 1996, 95:724-731.
133. Tomer A. A sensitive and specific functional flow cytometric assay for the diagnosis of heparin-induced thrombocytopenia. Br J Haematol 1997, 98:648-656.
134. Jy W., Mao W.W., Horstman L.L., et al. A flow cytometric assay of platelet activation markers P-selectin (CD62P) distinguishes heparin-induced thrombocytopenia (HIT) from HIT with thrombosis (HITT). Thromb Haemost 1999, 82:1255-1259.
135. Amiral J., Bridey F., Wolf M., et al. Antibodies to macromolecular platelet factor 4-heparin complexes in heparin-induced thrombocytopenia: A study of 44 cases. Thromb Haemost 1995, 73:21-28.
136. Newman P.M., Swanson R.L., Chong B.H. Heparin-induced thrombocytopenia: IgG binding to PF4- heparin complexes in the fluid phase and cross-reactivity with low molecular weight heparin and heparinoid. Thromb Haemost 1998, 80:292-297.
137. Eichler P., Raschke R., Lubenow N., et al. The new ID-heparin/PF4 antibody test for rapid detection of heparininduced antibodies in comparison with functional and antigenic assays. Br J Haematol 2002, 116:887-891.
138. Risch L., Bertschmann W., Heijnen I.A.F.M., et al. A differentiated approach to assess the diagnostic usefulness of a rapid particle gel immunoassay for the detection of antibodies against heparin-platelet factor 4 in cardiac surgery patients. Blood Coagul Fibinolysis 2003, 14:99-106.
139. Chong B.H., Magnani H. Heparin-induced thrombocytopenia 2004, 371-396. Basel, Marcel Dekker, New York. 3rd ed. T.E. Warkentin, A. Greinacher (Eds.).
140. Chong B.H., Magnani H.N. Orgaran in heparininduced thrombocytopenia. Haemostasis 1992, 22:85-91.
141. Magnani H.N. Heparin-induced thrombocytopenia. (HIT): An overview of 230 patients treated with orgaran (Org. 10172). Thromb Haemost 1993, 70:554-561.
142. Greinacher A., Völpel H., Janssens U., et al. Recombinant hirudin (Lepirudin) provides safe and effective anticoagulation in patients with the immunologic type of heparin-induced thrombocytopenia: A prospective study. Circulation 1999, 99:73-80.
143. Greinacher A., Janssens U., Berg G., et al. Lepirudin (recombinant hirudin) for parenteral anticoagulation in patients with heparin-induced thrombocytopenia. Circulation 1999, 100:587-593.
144. Lewis B.E., Hursting M.J. Heparin-induced thrombocytopenia 2004, 437-474. Basel, Marcel Dekker, New York. 3rd ed. T.E. Warkentin, A. Greinacher (Eds.).
145. Cohen J.I., Cooper M.R., Greenberg G.S. Streptokinase therapy of pulmonary emboli with heparinassociated thrombocytopenia. Arch Intern Med 1985, 145:1725-1726.
146. Fiessinger J.N., Aiach M., Rocanto M., et al. Critical ischemia during heparin-induced thrombocytopenia: Treatment by intra-arterial streptokinase. Thromb Res 1984, 33:235-238.
147. Cummings J.M., Mason T.J., Chomka E.V., et al. Fibrinolytic therapy of acute myocardial infarction in the heparin thrombosis syndrome. Am Heart J 1986, 112:407-409.
148. Sobel M., Adelman B., Szentpeterey S., et al. Surgical management of heparin-associated thrombocytopenia: Strategies in the treatment of venous and arterial thromboembolism. J Vasc Surg 1988, 8:395-401.
149. Meuleman D.G. Orgaran (Org. 10172): Its pharmacological profile in experimental models. Haemostasis 1992, 22:58-65.
150. Stiekema J.C., Eijnand H.P., van Dinther T.G., et al. Safety and pharmocokinetics of the low molecular weight heparinoid org. 10172 administered to healthy elderly volunteers. Br J Clin Pharmacol 1989, 27:39-48.
151. Danhof M., de Boer A., Magnani H.N., et al. Pharmacokinetic considerations on orgaran (org. 10172). Hemostasis 1992, 22:73-84.
152. Chong B.H., Gallus A.S., Cade J.F., et al. Prospective randomised open-label comparison of danaparoid with Dextran 70 in the treatment of heparin-induced thormbocytopneia with thrombosis: A clinical outcome study. Thromb Haemos 2001, 86:1170-1175.
153. Vun C.H., Evans S., Chong B.H. Cross-reactivity study of low molecular weight heparinoid in heparininduced thrombocytopenia. Thromb Res 1996, 81:523-525.
154. Warkentin T.E. Danaparoid (orgaran) for the treatment of heparin-induced thrombocytopenia (HIT) and thrombosis: Effects on in vivo thrombin and cross-linked fibrin generation and evaluation of the clinical significance of vitro cross-reactivity of danaparoid for HIT-IgG [abstr.]. Blood 1996, 88:626a.
155. Tardy-Poncet B., Mahul P., Beraud A.M., et al. Failure of orgaran therapy in a patient with a previous heparin-induced thrombocytopenia. Br J Haematol 1995, 90:69-70.
156. Clore G.M., Sukumaran D.K., Niges M., et al. The conformation of hirudin in solution: A study using nuclear magnetic resonance, distance geometry and restrained molecular dynamics. EMBO J 1987, 6:529-537.
157. Weitz J.I., Hudoba M., Massel D., et al. Clot bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin IIIindependent inhibitors. J Clin Invest 1990, 86:385-391.
158. Glusa E. Pharmacology and therapeutic applications of hirudin, a new anticoagulant. Kidney Int 1998, 53:54-56.
159. Eichler P., Lubenow N., Greinacher A. Results of the third prospective study of treatment with lepirudin in patients with heparin-induced thrombocytopenia (HIT) [abstr]. Blood 2002, 100(suppl 1):704a.
160. Greinacher A. Heparin-induced thrombocytopenia 2004, 397-437. 3rd ed.
161. Eichler P., Friesen H.J., Lubenow N., et al. Antihirudin antibodies in patients with heparin-induced thrombocytopenia treated with lepirudin: Incidence, effects of aPTT, and clinical relevance. Blood 2000, 2372-2378. Basel, Marcel Dekker, 96.
162. Okamoto S., Okunomiya-Hijikata A. Synthetic selective inhibitors of thrombin. Methods 1993, 222:328-340.
163. Berry C.N., Girardot C., Lecoffre C., et al. Effects of the synthetic thrombin inhibitor argatroban on fibrin- or clot-incorporated thrombin: Comparison with heparin and recombinan hirudin. Thromb Haemost 1994, 72:381-386.
164. Izawa O., Katsuki M., Komatsu T., et al. Pharmacokinetic studies of argatroban (MD-805) in human: Concentrations of argatroban and its metabolites in plasma, urine and feces during and after drip intravenous infusion. Jap Pharmacol Ther 1986, 14:251-263.
165. Swan S.K., St.Peter J.V., Lambrecht L.J., et al. Comparison of anticoagulant effects and safety of argatroban and heparin in healthy subjects. Pharmacotherapy 2000, 20:756-770.
166. Bartholomew J. Heparin-induced thrombocytopenia 2004, 475-507. Basel, Marcel Dekker, New York. 3rd ed. T.E. Warkentin, A. Greinacher (Eds.).
167. Robson R., White H., Aylward P., et al. Bivalirudin pharmacokinetics and pharmacodynamics: Effect of renal function, dose and gender. Clin Pharmacol Ther 2002, 71:433-439.
168. Chamberlin J.R., Lewis B., Leya F., et al. Successful treatment of heparin-associated thrombocytopenia and thrombosis using hrulog. Can J Cardiol 1994, 11:511-514.
169. Francis J., Drexler A., Gwyn G., et al. Bivalirubin, a direct thrombin inhibitor, in the treatment of heparininduced thrombocytopenia (abstr). Thromb Haemost 2003, 1(suppl 1):1909.
170. Boneu B., Necciari J., Cariou R., et al. Pharmacokinetics and tolerance of the natural pentasacchardie (ORG31540/SR90107A) with high affinity to antithrombin III in man. Thromb Haemost 1995, 74:1468-1473.
171. Buller H.R., Davidson B.L., Decousus H., et al. Subutaneous fondaparinux versus intravenous unfractionated heparin in the initial treatment of pulmonary embolism. N Engl J Med 2003, 349:1695-1702.
172. Kovacs M.J. Successful treatment of heparin induced thrombocytopenia. Thromb Haemost 2005, 93:999-1000.
173. D'Amico E.A., Villaca P.R., Gualandro S.F., et al. Successful use of arixtra in a patient with paroxysmal noctural hemoglobinuria, Budd-Chiari syndrome and heparininduced thrombocytopenia [letter]. J Thromb Haemost 2003, 1:2452-2453.
174. Parody R., Oliver A., Souto J.C., et al. Fondaparinux (ARIXTRA) as an alternative anti-thrombotic prophylaxis when there is hypersensitivity to low molecular weight and unfractionated heparins. Haematologica 2003, 88:32.
175. Gruel Y., Lermusiaux P., Lang M., et al. Usefulness of antiplatelet drugs in the management of heparin-associated thrombocytopenia and thrombosis. Ann Vasc Surg 1991, 5:552-555.
176. Frame J.N., Mulvey K.P., Phares J.C., et al. Correction of severe heparin-associated thrombocytopenia with intravenous immunoglobulin. Ann Intern Med 1989, 111:946-947.
177. Grau E., Linares M., Alaso M.A., et al. Heparininduced thrombocytopenia-response to intravenous immunoglobulin in vivo and in vitro. Am J Hematol 1992, 39:312.
178. Bouvier J.L., Lefevre P., Villain P., et al. Treatment of serious heparin-induced thrombocytopenia by plasma exchange: Report on four cases. Thromb Res 1988, 51:335-336.
179. Nand S., Robinson J.A. Plasmapheresis in the management of heparin-associated thrombocytopenia with thrombosis. Am J Hematol 1988, 28:204-206.
180. Thorp D., Canty A., Whiting J., et al. Plasma exchange and heparin-induced thrombocytopenia. Prog Clin Biol Res 1990, 337:521-522.
181. Leroy J., Leclerc M.H., Delahousse B., et al. Treatment of heparin-associated thrombocytopenia and thrombosis with low molecular weight heparin (C.Y. 216). Semin Thromb Hemost 1985, 11:326-329.
182. Vitoux J.F., Mathieu J.F., Roncato M., et al. Heparin-associated thrombocytopenia: Treatment of low molecular weight heparin. Thromb Haemost 1986, 55:37-39.
183. Gouault-Heilmann M., Huet Y., Adnot S., et al. Low molecular weight heparin fractions as an alternative therapy in heparin-induced thrombocytopenia. Haemostasis 1987, 17:134-140.
184. Chong B.H., Murray B., Berndt M.C., et al. Plasma P-selectin is increased in thrombotic consumptive platelet disorders. Blood 1994, 83:1535-1541.
185. Warkentin T.E., Kelton J.G. A 14-year study of heparin-induced thrombocytopenia. Am J Med 1996, 101:502-507.
186. Wallis D.E., Workman D.L., Lewis B.E., et al. Failure of early heparin cessation as treatment for heparininduced thrombocytopenia. Am J Med 1999, 106:629-635.
187. Reiss F.C., Poetzch B., Mueller-Berghaus G. New anticoagulants for the Cardiovascular Patient 1997, 197-222. R. Pifarré (Ed.).
188. Vasquez J.C., Vichiendilokkul A., Mahmood S., et al. Anticoagulation with bivalirudin during cardio pulmonary bypass in cardiac surgery. Ann Thorac Surg 2002, 2177-2179. Hanley & Belfus, 74.
189. Makhoul R.G., McCann R.L., Austin E.H., et al. Management of patients with heparin-associated thrombocytopenia and thrombosis requiring cardiac surgery. Ann Thorac Surg 1987, 43:617-621.
190. Laster J., Elfrin R., Silver D. Re-exposure to heparin of patients with heparin-associated antibodies. Vas Surg 1989, 9:677-681.
191. Kappa J.R., Fisher C.A., Todd B., et al. Intraoperative management of patients with heparin-induced thrombocytopenia. Ann Thoracic Surg 1990, 49:714-722.
192. Koster A., Hansen R., Kuppe H., et al. Recombinant hirudin as an alternative for anticoagulation during cardiopulmonary bypass in patients with heparin-induced thrombocytopenia type II: A 1-year experience in 57 patients. J Cardiothorac Vasc Anesth 2000, 14:243-248.
193. Koster A., Meyer O., Fischer T., et al. One-year experience with the platelet glycoprotein IIb/IIIa antagonist tirofiban and heparin during
194. Mertzlufft F., Kuppe H., Koster A. Management of urgent high-risk cardiopulmonary bypass in patients with heparin-induced thrombocytopenia type II and coexisting disorders of renal function: Use of heparin and epoprostenol combined with on-line monitoring of platelet function. J Cardothoac Vasc Anesth 2000, 14:304-308.
195. Warkentin T.E., Dunn G.L., Cybulsky I.J. Offpump coronary artery bypass grafting for acute heparininduced thrombocytopenia. Ann Thorac Surg 2001, 72:1730-1732.
196. Kieta D.R., McCammon A.T., Homan W.T., et al. Hemostatic analysis of a patient undergoing offpump coronary artery bypass surgery with argatroban anticoagulation. Anesth Analg 2003, 96:956-958.
197. Merry A.F., Raudkivi P.J., Middleton N.G., et al. Bivalirudin versus heparin and procamine in off pump coronary artery bypass surgery. Ann Thorac Surg 2004, 77:925-931.
198. Carrier M., Robitaille D., Perrault L.P., et al. Heparin vs. danaparoid in off-pump coronary bypass grafting: Results of a prospective randomized clinical test. J Thorac Cardiovasc Surg 2003, 125:325-329.
199. Mahaffey K.W., Lewis B.E., Wildermann N.M., et al. The anticoagulant therapy with bivalirudin to assist in the performance of percutaneous coronary intervention in patients with heparin-induced thrombocytopenia (ATBAT) study: Main results. J Invasive Cardiol 2003, 15:611-616.
200. Manfredi J.A., Wall R.P., Sane D.C., et al. Lepirudin as a safe alternative for effective anticoagulation in patients with know heparin-induced thrombocytopenia undergoing a percutaneous coronary intervention: Case reports. Cathet Cardiovasc Interv 2001, 52:468-472.
201. Rupprecht H.J., Terres W., Ozbek C., et al. Recombinant hirudin (HBW 023) prevents troponin T release after coronary angioplasty in patients with unstable angina. J Am Coll Cardiol 1995, 26:1637-1642.
202. Van Wyk V., Badenhorst P.N., Luus H.G., et al. A comparison between the use of recombinant hirudin and heparin during hemodialysis. Kidney Int 1995, 48:1338-1343.
203. Nowak G., Bucha E., Brauns I., et al. Anticoagulation with r-hirudin in regular application of r-hirudin in a haemodialysis patient. Wien Klin Wochenschr 1997, 109:354-358.
204. Matsuo T., Kario K., Kodama K., et al. Clinical application of the synthetic thrombin inhibitor, argatroban (MD-805). Semin Thromb Hemost 1992, 18:155-160.
205. Koide M., Yamamoto S., Matsuo M., et al. Anticoagulation for heparin-induced thrombocytopenia with spontaneous platelet aggregation in a patient requiring haemodialysis. Nephrol Dial Transplant 1995, 10:2137-2140.
206. Fischer K-G. Heparin-induced thrombocytopenia 2004, 335-370. Basel, Marcel Dekker, New York. 3rd ed. T.E. Warkentin, A. Greinacher (Eds.).
207. Klenner A.F., Greinacher A. Heparin-induced thrombocytopenia 2004, 553-571. Basel, Marcel Dekker, New York. 3rd ed. T.E. Warkentin, A. Greinacher (Eds.).